newsfilter
← Latest News
PR Newswire·

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Senior Partner James (Josh) Wilson is encouraging investors with significant losses in Tvardi stock or options to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Tvardi's shares plummeted over 80% on Monday, October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101.
  • The clinical trial was designed to assess safety, pharmacokinetics, & exploratory outcomes regarding lung function in idiopathic pulmonary fibrosis.
  • The study did not meet its goals after preliminary data showed that percent predicted Forced Vital Capacity (FVC) was lower in placebo-treated patients compared to TTI-101-treated arms.
  • Investors can access more information about the investigation at www.faruqilaw.com/TVRD or by contacting the firm directly.
  • Faruqi & Faruqi, LLP is a national securities law firm with offices in New York, Pennsylvania, California, & Georgia that has recovered hundreds of millions of dollars for investors since 1995.